ImClone.com

Sat, Feb 4, 2012

09/23/09	Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
09/21/09	Lilly Names New Business Leaders
09/21/09	Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients
07/22/09	Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
07/20/09	ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
03/02/09	ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX® in U.S.
01/23/09	ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX®
12/08/08	ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted To U.S. Food and Drug Administration
11/24/08	Lilly Completes Acquisition of ImClone Systems
11/21/08	Lilly Completes Cash Tender Offer for ImClone Systems
11/20/08	ImClone Systems' State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production
11/19/08	Randomized Phase 2 Study of IMC-A12 for HER2-Expressing Advanced Breast Cancer Commences Patient Enrollment
11/17/08	ImClone Systems Announces Clearance of Tender Offer by German Federal Cartel Office
11/11/08	Phase 2 Study of IMC-1121B in First-Line Treatment of Advanced Non-Small Cell Lung Cancer Commences Patient Enrollment
11/05/08	ImClone Systems Announces Expiration of Hart-Scott-Rodino Waiting Period
10/30/08	ERBITUX® Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration
10/29/08	ImClone Announces ERBITUX® Commercial Launch in Canada for Advanced Colorectal Cancer
10/22/08	Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX® Treatment
10/06/08	Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
10/06/08	ImClone Announces Merger Agreement with Eli Lilly at $70 Per Share
10/01/08	ImClone Systems Issues Statement
09/30/08	Phase 2 Study of IMC-1121B for Advanced Ovarian Cancer Commences Patient Enrollment
09/29/08	ImClone Systems Issues Statement
09/25/08	Randomized Phase 2 Study of IMC-A12 for Advanced Breast Cancer Commences Patient Enrollment
09/23/08	Icahn Responds to Cornelius
09/22/08	ERBITUX® Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer
09/19/08	ERBITUX® Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
09/16/08	ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
09/11/08	ImClone Systems Submits Letter to Bristol-Myers Squibb
09/10/08	Study Published in New England Journal of Medicine Shows ERBITUX® Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer
09/10/08	ImClone Systems Issues Statement
09/03/08	ImClone Submits Supplemental Biologics License Application for ERBITUX® in First-Line Head and Neck Cancer
08/29/08	ERBITUX® Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
08/26/08	Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
08/13/08	Global Phase 3 Study of IMC-1121B in Metastatic Breast Cancer Commences
08/04/08	ImClone Systems Issues Statement
07/31/08	ImClone Systems Issues Statement
07/24/08	ImClone Systems Reports Second Quarter 2008 Financial Results
07/18/08	ImClone Systems to Host Second Quarter 2008 Financial Results Conference Call
07/16/08	ERBITUX® (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
07/14/08	ImClone Announces Changes in Commercial Organization Leadership
07/07/08	Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient Enrollment
06/25/08	IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient Enrollment
06/06/08	ImClone Systems to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
06/02/08	ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
06/01/08	New Analyses of Pivotal Phase 3 Study of ERBITUX® Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
05/31/08	RTOG Study: Adding Cetuximab to Chemotherapy and Radiotherapy Leads to Improved Outcome for Lung Cancer Patients
05/31/08	ERBITUX® (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
05/30/08	ImClone to Host Investor Reception on June 1, 2008 to Discuss Data Presented at the American Society of Clinical Oncology Annual Meeting
05/20/08	Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient Enrollment
05/19/08	ImClone Systems to Present at the 2008 Citi Investment Research Global Health Care Conference
05/16/08	ERBITUX® (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
05/16/08	Significant Data on ERBITUX® (cetuximab) and ImClone Pipeline to Be Presented at American Society of Clinical Oncology 2008 Annual Meeting
05/13/08	Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment
05/12/08	ImClone Systems to Present at the Bank of America 2008 Healthcare Conference
04/24/08	ImClone Systems Reports First Quarter 2008 Financial Results
04/22/08	ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
04/18/08	ImClone Systems to Host First Quarter 2008 Financial Results Conference Call
04/09/08	Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient Enrollment
03/31/08	ImClone Appoints Kenneth J. Zuerblis Chief Financial Officer
03/11/08	ImClone Systems to Present at the Cowen and Company 28th Annual Health Care Conference
03/05/08	Phase I/II Studies of IMC-A12 in Pediatric Cancer Patients Commence Enrollment
02/22/08	Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
02/04/08	ImClone Systems to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
01/31/08	ImClone Systems Reports Fourth Quarter and Full Year 2007 Financial Results
01/21/08	ImClone Systems to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call
01/14/08	ImClone Systems to Present at the Stanford Group Company 13th Annual Healthcare Conference
01/03/08	ImClone Systems to Present at the 26th Annual JPMorgan Healthcare Conference

Company Overview | Pipeline | Grant Requests | News | Careers